Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111208 | 1.00 | PPARA (0.55) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL1111209 | 1.00 | PPARA (0.55) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL7515531 | 0.91 | FOLH1 (0.58) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL6841663 | 0.91 | FOLH1 (0.58) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL6059278 | 0.91 | CTSK (0.54) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL7215503 | 0.91 | CTSK (0.54) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL600823 | 0.90 | FOLH1 (0.60) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL26641195 | 0.90 | FOLH1 (0.60) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL19658555 | 0.90 | FOLH1 (0.60) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL9830736 | 0.90 | TGM2 (0.50) | PPARAPPARGCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| EP-1133476-A1 | IMINOGUANIDINE DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2001-09-19 | — | — | EP | claimed |
| WO-2000031044-A1 | IMINOGUANIDINE DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2000-06-02 | — | — | WO | claimed |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| CN-119866342-A | Cyclic peptides for capturing interleukin-1 beta | 默沙东有限责任公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119372125-A | Engineering escherichia coli for producing O-succinyl-L-homoserine as well as construction method and application thereof | 浙江工业大学 | 2025-01-28 | — | — | CN | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-114835729-B | Inhibitor containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-5627278-A | MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION | BRISTOL-MYERS SQUIBB CO. (US) | 1997-05-06 | — | — | US | disclosed |
| US-5616775-A | ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE | BRISTOL-MYERS SQUIBB CO. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5508272-A | SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5496834-A | PEPTIDE DERIVATIVES AS CATHEPSIN L INHIBITORS AND INHIBITORS OF BONE RESORPTION OR TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0641800-A1 | Lactol derivatives as inhibiters of cathepsin L | Takeda Chemical Industries, Ltd. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0629627-A2 | Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0230037-B1 | CYTOPROTECTIVE DERIVATIVES USEFUL IN ISCHEMIC DISEASES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | ITALFARMACO S.p.A. (IT) | 1991-03-06 | — | — | EP | disclosed |
| US-4789681-A | CARDIOPROTECTIVE AGENTS | ITALFARMACO S.P.A. (IT) | 1988-12-06 | — | — | US | disclosed |
| EP-0230037-A1 | Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them | ITALFARMACO S.p.A. (IT) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | PPARA 1780/4885PPARG 1592/4885CTSK 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.